Blog icon

19 August 2020 Statement

CSIRO also welcomes the news that the Australian Government is working with CSL and AstraZeneca to assess whether it is possible to provide local manufacturing support for the vaccine, should it prove successful.

As Australia’s national science agency, CSIRO is playing a critical role in the global efforts to develop a COVID-19 vaccine. In March this year, the Coalition for Epidemic Preparedness Innovations (CEPI) engaged CSIRO to undertake a preclinical trial of Oxford’s vaccine candidate at the Australian Centre for Disease Preparedness (ACDP). ACDP is CSIRO’s high-containment biosecurity facility, the only lab of its kind in the southern hemisphere.

CSIRO has shared early data from the preclinical trial with CEPI and Oxford University, which enabled the vaccine candidate to progress on to phase 3 clinical (human) trials.

While preliminary reports have shown Oxford’s vaccine candidate generates an immune response, there’s still a long way to go before a viable vaccine is widely accessible. The results of the phase 3 clinical trials will show if the vaccine candidate is efficacious and safe for the broader population.

Contact us

Find out how we can help you and your business. Get in touch using the form below and our experts will get in contact soon!

CSIRO will handle your personal information in accordance with the Privacy Act 1988 (Cth) and our Privacy Policy.

First name must be filled in

Surname must be filled in

I am representing *

Please choose an option

Please provide a subject for the enquriy

0 / 100

We'll need to know what you want to contact us about so we can give you an answer

0 / 1900

You shouldn't be able to see this field. Please try again and leave the field blank.